XORTX Therapeutics Inc.XRTX

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Canada · xortx.com

XORTX Therapeutics Inc. is a Canadian late-stage clinical pharmaceutical company focused on developing therapies that modulate uric acid pathways to treat kidney diseases and metabolic conditions. Its pipeline includes XRx-026 (Phase 3) for gout, XRx-008 (Phase 2) for autosomal dominant polycystic kidney disease, and XRx-101 (Phase 2) for acute kidney injury associated with respiratory virus infection. The company is headquartered in Calgary, Alberta.

Key ratios

ROA

-46.8%TTM

2025 -46.8%2024 -34.2%2023 -34.7%

ROE

-98.0%TTM

2025 -98.0%2024 -83.1%2023 -37.1%

Recent news

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO, Targeting USD$700M+ U.S. Gout Market Opportunity 2026-09-18 · GlobeNewswire XORTX Re-Engages Investor Relations Program 2026-09-08 · GlobeNewswire XORTX Announces Termination and Postponement of Investor Relations Program 2026-08-28 · GlobeNewswire XORTX Announces Director Resignation 2026-07-31 · GlobeNewswire XORTX Appoints New Director 2026-07-29 · GlobeNewswire XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO 2026-06-15 · XORTX Therapeutics XORTX Confirms Effective Date of Share Consolidation 2026-04-01 · XORTX Therapeutics XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems 2026-02-04 · XORTX Therapeutics

Track XRTX in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer